Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Orthofix’s foreign corruption woes: 5 things you can learn

March 6, 2017 By Chris Newmarker

Marc Alain Bohn, Miller & Chevalier

foreign corruption medtech

[Image courtesy of Ambro on FreeDigitalPhotos.net]

Orthofix International in January entered into its second Foreign Corrupt Practices Act (FCPA) settlement in less than 5 years, resolving allegations with the U.S. Securities and Exchange Commission that the company’s Brazilian subsidiary made improper payments to doctors at government-owned hospitals in Brazil to increase sales.

Orthofix consented to the entry of two SEC orders instituting cease-and-desist proceedings against the company: a $6.1 million order centered on alleged violations of the FCPA and an $8.25 million order focused on non-bribery-related securities violations.

The FCPA prohibits corruptly providing anything of value to a “foreign official,” including doctors at state-owned hospitals, for the purpose of obtaining or retaining business. It also requires U.S. securities issuers to maintain accurate books and records and implement sufficient internal accounting controls.

Orthofix (Lewisville, Texas) self-disclosed the FCPA issues at its Brazilian subsidiary per the terms of its 2012 deferred prosecution agreement (DPA) with the Department of Justice (DOJ).  DOJ and the SEC followed up with new investigations, and DOJ twice extended the DPA term while the investigation was pending. The DOJ ultimately decided to take no further action and allowed the DPA to expire in August 2016.  The SEC came to a different conclusion.

The Orthofix case serves as a cautionary tale for companies trying to stay out of trouble and offers five clear lessons:

  1. Standardize or centralize approval of third party commissions and discounts. According to the SEC, Orthofix’s decentralized structure allowed its Brazilian subsidiary to (a) easily evade existing policies and controls to pay high commissions and discounts that funded improper payments; and (b) record these expenses as legitimate.
  2. Actively monitor payments and discounts provided to third-party intermediaries to ensure they are reasonable and consistent with contract terms. The SEC alleged that Orthofix channeled bribes through its third-party sales representatives and distributors in several ways, including paying inflated commissions, providing excessive discounts, and paying for services never rendered.
  3. Fully and promptly remediate compliance issues when they arise. According to the SEC, Orthofix failed to remediate the compliance issues identified in its 2012 enforcement action. As a result, gaps in the company’s third party controls persisted and were not addressed until after the discovery of the Brazil conduct in late 2013.
  4. Ensure periodic training to relevant employees and, where appropriate, key third parties to prioritize compliance and keep channels of communication open. The SEC Order asserts that in addition to gaps in controls, Orthofix lacked adequate training and a corporate culture to enable Brazilian employees to raise compliance concerns to the parent level.
  5. Conduct periodic compliance-focused audits and assessments, particularly in high-risk markets. The SEC Order suggests that Orthofix ultimately identified the Brazil conduct in late 2013 because of efforts the company was making to improve its compliance program following its 2012 enforcement action.

While it is not possible to eliminate corruption risk, medical device companies are much more likely to avoid running afoul of the FCPA if they can learn from Orthofix’s missteps and continue to update their programs to confront evolving compliance challenges.

Marc Bohn is Counsel in the FCPA & International Anti-Corruption Practice at Miller & Chevalier in Washington, D.C.

Related Articles Read More >

Philips
Philips updates on testing results for recalled ventilators
Medtronic HeartWare HVAD
Another Medtronic HVAD recall is serious
A cylindrical-shaped medical device with a blue cap on one end and a brown cap on the other
How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
FDA logo
FDA seeking innovations to move beyond heater-cooler device problems

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech